248 related articles for article (PubMed ID: 21949853)
1. Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease.
Prabakaran T; Nielsen R; Larsen JV; Sørensen SS; Feldt-Rasmussen U; Saleem MA; Petersen CM; Verroust PJ; Christensen EI
PLoS One; 2011; 6(9):e25065. PubMed ID: 21949853
[TBL] [Abstract][Full Text] [Related]
2. Mannose 6-phosphate receptor and sortilin mediated endocytosis of α-galactosidase A in kidney endothelial cells.
Prabakaran T; Nielsen R; Satchell SC; Mathieson PW; Feldt-Rasmussen U; Sørensen SS; Christensen EI
PLoS One; 2012; 7(6):e39975. PubMed ID: 22768187
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice.
Meng XL; Day TS; McNeill N; Ashcraft P; Frischmuth T; Cheng SH; Liu ZP; Shen JS; Schiffmann R
J Inherit Metab Dis; 2016 May; 39(3):447-455. PubMed ID: 26960552
[TBL] [Abstract][Full Text] [Related]
4. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy.
Braun F; Abed A; Sellung D; Rogg M; Woidy M; Eikrem O; Wanner N; Gambardella J; Laufer SD; Haas F; Wong MN; Dumoulin B; Rischke P; Mühlig A; Sachs W; von Cossel K; Schulz K; Muschol N; Gersting SW; Muntau AC; Kretz O; Hahn O; Rinschen MM; Mauer M; Bork T; Grahammer F; Liang W; Eierhoff T; Römer W; Hansen A; Meyer-Schwesinger C; Iaccarino G; Tøndel C; Marti HP; Najafian B; Puelles VG; Schell C; Huber TB
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37014703
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss.
Najafian B; Tøndel C; Svarstad E; Gubler MC; Oliveira JP; Mauer M
J Am Soc Nephrol; 2020 Apr; 31(4):865-875. PubMed ID: 32127409
[TBL] [Abstract][Full Text] [Related]
7. α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes.
Jehn U; Bayraktar S; Pollmann S; Van Marck V; Weide T; Pavenstädt H; Brand E; Lenders M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768768
[TBL] [Abstract][Full Text] [Related]
8. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice.
Christensen EI; Zhou Q; Sørensen SS; Rasmussen AK; Jacobsen C; Feldt-Rasmussen U; Nielsen R
J Am Soc Nephrol; 2007 Mar; 18(3):698-706. PubMed ID: 17287429
[TBL] [Abstract][Full Text] [Related]
9. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
[TBL] [Abstract][Full Text] [Related]
10. Dysregulated autophagy contributes to podocyte damage in Fabry's disease.
Liebau MC; Braun F; Höpker K; Weitbrecht C; Bartels V; Müller RU; Brodesser S; Saleem MA; Benzing T; Schermer B; Cybulla M; Kurschat CE
PLoS One; 2013; 8(5):e63506. PubMed ID: 23691056
[TBL] [Abstract][Full Text] [Related]
11. Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR/Cas9 technology.
Pereira EM; Labilloy A; Eshbach ML; Roy A; Subramanya AR; Monte S; Labilloy G; Weisz OA
Am J Physiol Renal Physiol; 2016 Nov; 311(5):F1015-F1024. PubMed ID: 27681560
[TBL] [Abstract][Full Text] [Related]
12. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy.
Sanchez-Niño MD; Sanz AB; Carrasco S; Saleem MA; Mathieson PW; Valdivielso JM; Ruiz-Ortega M; Egido J; Ortiz A
Nephrol Dial Transplant; 2011 Jun; 26(6):1797-802. PubMed ID: 20504837
[TBL] [Abstract][Full Text] [Related]
13. Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice.
Shen JS; Busch A; Day TS; Meng XL; Yu CI; Dabrowska-Schlepp P; Fode B; Niederkrüger H; Forni S; Chen S; Schiffmann R; Frischmuth T; Schaaf A
J Inherit Metab Dis; 2016 Mar; 39(2):293-303. PubMed ID: 26310963
[TBL] [Abstract][Full Text] [Related]
14. Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice.
Higuchi K; Yoshimitsu M; Fan X; Guo X; Rasaiah VI; Yen J; Tei C; Takenaka T; Medin JA
Mol Med; 2010; 16(5-6):216-21. PubMed ID: 20454522
[TBL] [Abstract][Full Text] [Related]
15. Expression of genes and their responses to enzyme replacement therapy in a Fabry disease mouse model.
Park ES; Choi JO; Park JW; Lee MH; Park HY; Jung SC
Int J Mol Med; 2009 Sep; 24(3):401-7. PubMed ID: 19639234
[TBL] [Abstract][Full Text] [Related]
16. Naked plasmid DNA-based alpha-galactosidase A gene transfer partially reduces systemic accumulation of globotriaosylceramide in Fabry mice.
Nakamura G; Maruyama H; Ishii S; Shimotori M; Kameda S; Kono T; Miyazaki J; Kulkarni AB; Gejyo F
Mol Biotechnol; 2008 Feb; 38(2):109-19. PubMed ID: 18219591
[TBL] [Abstract][Full Text] [Related]
17. One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease.
Najafian B; Tøndel C; Svarstad E; Sokolovkiy A; Smith K; Mauer M
PLoS One; 2016; 11(4):e0152812. PubMed ID: 27081853
[TBL] [Abstract][Full Text] [Related]
18. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
[TBL] [Abstract][Full Text] [Related]
19. Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.
Blom D; Speijer D; Linthorst GE; Donker-Koopman WG; Strijland A; Aerts JM
Am J Hum Genet; 2003 Jan; 72(1):23-31. PubMed ID: 12471562
[TBL] [Abstract][Full Text] [Related]
20. A heterozygous female with Fabry disease due to a novel α-galactosidase A mutation exhibits a unique synaptopodin distribution in vacuolated podocytes.
Takahashi N; Yokoi S; Kasuno K; Kogami A; Tsukimura T; Togawa T; Saito S; Ohno K; Hara M; Kurosawa H; Hirayama Y; Kurose T; Yokoyama Y; Mikami D; Kimura H; Naiki H; Sakuraba H; Iwano M
Clin Nephrol; 2015 May; 83(5):301-8. PubMed ID: 25295576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
